BioXmark®, manufactured by Nanovi Publications & Abstracts

Bladder Cancer

de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. BJR. 2020 Jun 1;20200241. https://pubmed.ncbi.nlm.nih.gov/32463291/

de Ridder M, Gerbrandy LC, De Reijke TM, Hinnen KA, Hulshof MCCM. A novel liquid fiducial marker for image-guided adaptive radiotherapy in bladder cancer [poster at ESTRO 2020]. https://www.estro.org/library/item/7004/a-novel-liquid-fiducial-marker-for-image-guided-adaptive-radiotherapy-in-bladder-cancer

Hafeez S, Hansen VN, McNair H, Harris E, Jones K, Schmidt M, Kumar P, Huddart R. Assessing feasibility of a new fundicial marker (BioXmark) for bladder tumor localization and position verification during radical radiotherapy in a porcine phantom. Abstract 30th EUS Annual Meeting, New Orleans, LA, 2015 May 16.
http://engineering-urology.org/am/30EUS_2015.pdf (Abstract 8; P: 22)

Esophageal Cancer

Machiels M, Voncken FEM, Jin P, Dieren JM van, Bartels-Rutten A, Alderliesten T, Aleman BMP, Hooft JE van, Hulshof MCCM. A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Practical Radiation Oncology. 2019 Nov 1;9(6): e506–15.
https://pubmed.ncbi.nlm.nih.gov/31279938/

de Blanck SR, Scherman-Rydhög J, Siemsen M, Christensen M, Baeksgaard L, Irming Jølck R, Specht L, Andresen TL, Persson GF. Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of esophageal cancer. Br J Radiol. 2018 Dec;91(1092):20180236.
https://pubmed.ncbi.nlm.nih.gov/29975152/

Jelvehgaran P, Alderliesten T, Weda JJA, de Bruin M, Faber DJ, Hulshof MCCM, van Leeuwen TG, van Herk M, de Boer JF. Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study. Med Phys. 2017 Dec;44(12):6570–82.
https://www.ncbi.nlm.nih.gov/pubmed/29023771

Stomach and Other Upper GI Cancers

Bleeker M, Hulshof MCCM, Bel A, Sonke JJ, van der Horst A. Stomach motion and deformation: implications for pre-operative gastric cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2023 Aug 24:S0360-3016(23)07844-6. doi: 10.1016/j.ijrobp.2023.08.049. Epub ahead of print. PMID: 37633498.
https://pubmed.ncbi.nlm.nih.gov/37633498/

Bleeker M, van der Horst A, Bel A, Sonke JJ, van Hooft JE, Pouw RE, Hulshof MCCM. Endoscopically placed fiducial markers for image-guided radiotherapy in preoperative gastric cancer: Technical feasibility and potential benefit. Endosc Int Open. 2023 Sep 21;11(9):E866-E872. doi: 10.1055/a-2129-2840. PMID: 37745837.
https://pubmed.ncbi.nlm.nih.gov/37745837/

Stefanowicz S, Möller ML, Thiele J, Jaster M, Hoinkis C, Troost EGC. Novel fiducial marker has optimal characteristics for image-guided radiotherapy of abdominal tumours. In ES: DRAFT EDITORS S.L.; 2020 [cited 2022 Sep 28]. Available poster from: https://www.postersessiononline.eu/173580348_eu/congresos/ESTRO2020/aula/-PO_1669_ESTRO2020.pdf

Head & Neck Cancer

Steybe D, Russe MF, Ludwig U, Sprave T, Vach K, Semper-Hogg W, Schmelzeisen R, Voss PJ, Poxleitner P. Intraoperative marking of the tumour resection surface for improved radiation therapy planning in head and neck cancer: preclinical evaluation of a novel liquid fiducial marker. Dentomaxillofac Radiol. 2021 Mar 1;50(3):20200290.
https://pubmed.ncbi.nlm.nih.gov/32915672/

Steybe D, Poxleitner P, Voss PJ, Metzger MC, Schmelzeisen R, Bamberg F, Kim S, Russe MF. Evaluation of computed tomography settings in the context of visualization and discrimination of low dose injections of a novel liquid soft tissue fiducial marker in head and neck imaging. BMC Med Imaging. 2021 Oct 27;21(1):157.
https://pubmed.ncbi.nlm.nih.gov/34702192/

Clerc-Renaud B, Boss M-K, Griffin LR, LaRue SM, Leary D. Potential for BioXmark liquid fiducial marker to improve identification of superficial component of canine oral tumors for computer-based radiation therapy planning. Can Vet J. 2019 Oct;60(10):1072–80.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741831/

Lung Cancer

de Blanck SR, Rydhög JS, Larsen KR, Clementsen PF, Josipovic M, Aznar MC, af Rosenschöld PM, Jølck RI, Specht L, Andresen TL, Persson GF. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology. 2018 Nov; 13:24–8.
https://pubmed.ncbi.nlm.nih.gov/30258990/

Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Irming Jølck R, Larsen KR, Clementsen P, Lars Andersen T, Poulsen PR, Fredberg Persson G, Munck af Rosenschold P. Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiotherapy and Oncology. 2017 Apr;123(1):78–84.
https://www.ncbi.nlm.nih.gov/pubmed/28245908

Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølck RI, Josipovic M, Aznar MC, Specht L, Andresen TL, Rosenschöld PM af, Persson GF. Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiotherapy and Oncology. 2016 Oct;121(1):64–9.
https://pubmed.ncbi.nlm.nih.gov/27443450/

Rydhög Scherman J, Perrin R, Jølck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck af Rosenschold P. Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology. 2017 Mar;122(3):393–9.
https://pubmed.ncbi.nlm.nih.gov/28104299/

Scherman JR, Irming Jølck R, Andresen TL, Munck af Rosenschöld P. Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy: A new liquid fiducial marker for IGRT. Med Phys. 2015 May 15;42(6Part1):2818–26.
https://www.ncbi.nlm.nih.gov/pubmed/26127034

Pancreatic Cancer

Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL. Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI. Strahlenther Onkol. 2019 Aug;195(8):756–63.
https://pubmed.ncbi.nlm.nih.gov/31143995/

Schneider S, Jølck RI, Troost EGC, Hoffmann AL. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom. Med Phys. 2018 Jan;45(1):37–47.
https://www.ncbi.nlm.nih.gov/pubmed/29136287

Dobiasch S, Kampfer S, Burkhardt R, Schilling D, Schmid TE, Wilkens JJ, Combs SE. BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid fiducial marker. Strahlenther Onkol. 2017 Dec;193(12):1039–47.
https://www.ncbi.nlm.nih.gov/pubmed/28808749

Rectal Cancer

Opbroek TJS, Willems YCP, Verhaegen F, de Ridder R, Hoge C, Melenhorst J, Bakers F, Grabsch HI, Buijsen J, Van Limbergen EJ, Canters RAM, Berbée M. BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial. Clinical and Translational Radiation Oncology. 2022 Nov;38:90–5.
https://pubmed.ncbi.nlm.nih.gov/36407490/

Willems YCP, Canters R, Timans L, Opbroek T, Verhaegen F, Van Limbergen EJ, Berbée M. PTV margin analysis for radiotherapy tumor boosting in rectal cancer using BioXmark® liquid fiducials [Poster at ESTRO 2022]
https://www.estro.org/Congresses/ESTRO-2022/666/implementationofnewtechnologyandtechniques/11271/ptvmarginanalysisforradiotherapytumorboostinginrec

Berbée M, Opbroek T, Paulissen J, Houben R, Van Limbergen E, Ta B, Steenbakkers I, Verhaegen F, de Ridder R, Jansen R, Melenhorst J, Bakers F, Grabsch H, Buijsen J, Canters R. BioXmark liquid fiducials to enable radiotherapy tumor boosting in rectal cancer feasibility trial. [Poster at ESTRO 2020]
https://www.estro.org/Congresses/ESTRO-2020/192/physicstrack-implementationofnewtechnology-techniq/412/bioxmarkliquidfiducialstoenableradiotherapytumorbo

Development of Technology

Wang W, Hansen AE, Sun H, Fliedner FP, Kjaer A, Jensen AI, Andresen TL, Henriksen JR. Carbohydrate based biomarkers enable hybrid near infrared fluorescence and ^{64}Cu based radio-guidance for improved surgical precision. Nanotheranostics. 2021;5(4):448–60.
https://pubmed.ncbi.nlm.nih.gov/34055574/

Hansen AE, Henriksen JR, Jølck RI, Fliedner FP, Bruun LM, Scherman J, Jensen AI, Munck Af Rosenschöld P, Moorman L, Kurbegovic S, de Blanck SR, Larsen KR, Clementsen PF, Christensen AN, Clausen MH, Wang W, Kempen P, Christensen M, Viby NE, Persson G, Larsen R, Conradsen K, McEvoy FJ, Kjaer A, Eriksen T, Andresen TL. Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Sci Adv. 2020 Aug 19;6(34)
https://pubmed.ncbi.nlm.nih.gov/32875113/

Bertholet J, Knopf A, Eiben B, McClelland J, Grimwood A, Harris E, Menten M, Poulsen P, Nguyen DT, Keall P, Oelfke U. Real-time intrafraction motion monitoring in external beam radiotherapy. Phys Med Biol. 2019 Aug;64(15):15TR01.
https://pubmed.ncbi.nlm.nih.gov/31226704/

Troost E, Menkel S, Enghardt W, Hytry J, Kunath D, Makocki S, Hoffmann A, Jølck R. EP-1710: Chemical stability of BioXmark® following normofractionated and single-fraction proton beam therapy. Radiotherapy and Oncology. 2017 May 1;123:S937–8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6871657/

Rydhög JS, Jølck RI, Andresen TL, Rosenschöld PM af. PO-0964: Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR. Radiotherapy and Oncology. 2015 Apr 1;115: S510.
http://nanovi.com/wp-content/uploads/2021/08/Rydhog-J-et-al.-poster.pdf

Evaluation of Safety and Feasibility of BioXmark

Brown KH, Ghita M, Schettino G, Prise KM, Butterworth KT. Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications. Cancers (Basel). 2020 May 18;12(5):1276. doi: 10.3390/cancers12051276.
https://pubmed.ncbi.nlm.nih.gov/32443537/

Mortensen SR, Scherman JB, Larsen KR, Jølck RI, Persson GF, Hansen AE, Eriksen T, Specht L. Use of a Novel Liquid Fiducial Marker Injected with Endoscopic Ultrasound Equipment for Use in Image Guided Radiation Therapy of Thoracic Tumors (Porcine Model). International Journal of Radiation Oncology Biology Physics. 2014 Sep 1;90(1): S651.
http://www.redjournal.org/article/S0360-3016(14)02577-2/abstract

Hamming VC, Brouwer CL, Van Goethem MJ, Jolck RI, Van Leijsen C, Van den Bergh ACM. PO-0866: Visibility, image artifacts and proton dose perturbation of fiducial markers. Radiotherapy and Oncology. 2017 May;123:S471–2.
https://www.thegreenjournal.com/article/S0167-8140(17)31303-8/pdf

Ericksen T, Mauldin N, Dickinson R, Mauldin G. Single high-dose radiation therapy and liquid fiducial markers can be used in dogs with incompletely resected soft tissue sarcomas. J Am Vet Med Assoc. 2023 Jul 12;261(10):1-8. doi: 10.2460/javma.23.02.0119.
https://pubmed.ncbi.nlm.nih.gov/37437890/